erlotinib hydrochloride has been researched along with Digestive System Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brierley, R | 1 |
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
1 trial(s) available for erlotinib hydrochloride and Digestive System Neoplasms
Article | Year |
---|---|
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
1 other study(ies) available for erlotinib hydrochloride and Digestive System Neoplasms
Article | Year |
---|---|
14th World Congress on Gastrointestinal Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Digestive System Neoplasms; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Fluorouracil; Genotype; Humans; Molecular Targeted Therapy; Pharmacogenetics; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins | 2012 |